Key Highlights

• Gossamer Bio Inc. (NASDAQ: GOSS) established an initial conversion rate of 5,347.5936 shares per $1,000 principal for its 7.50% convertible notes due 2030.

• Warrants to purchase common stock will carry an initial exercise price of $0.34 per share.

• The terms apply to the company’s secured first-lien convertible notes maturing in 2030.

Terms Finalized for 2030 Notes

Gossamer Bio Inc. (NASDAQ: GOSS) disclosed key financial terms for its upcoming debt instruments, marking a pivotal step in its capital strategy. The biopharmaceutical company outlined conversion and exercise rates for its 7.50% convertible senior secured notes due in 2030, providing clarity for investors evaluating its balance sheet.

Conversion Rate Details

Gossamer Bio determined that each $1,000 of principal on the 2030 convertible notes converts into 5,347.5936 shares of its common stock. This translates to a conversion price that is roughly $0.19 per share, a metric that will influence potential dilution and investor returns. The terms reflect current market conditions and the company’s equity valuation.

Warrant Exercise Price

Alongside the notes, Gossamer Bio established an initial exercise price of $0.34 per share for the associated purchase warrants. These warrants enable holders to acquire common stock at the set price, adding another layer to the company’s financing structure. The pricing aligns with the broader terms of the convertible debt offering.

Debt Instrument Structure

The 7.50% convertible notes are secured by a first‑lien position, prioritizing them in the capital stack. Due in 2030, the notes carry a fixed interest rate, providing a predictable cost of capital for the company. Investors will weigh the conversion terms against the yield and security of the debt.

Market Implications

A conversion price near $0.19 per share suggests a notable discount to recent trading levels, potentially encouraging noteholders to convert early. The $0.34 warrant exercise price further shapes the economics of the offering, influencing shareholder dilution and capital efficiency. Analysts will monitor how these terms affect Gossamer Bio’s liquidity and growth prospects.

Regulatory Compliance

The disclosure complies with the Securities Exchange Act of 1934, ensuring transparency for public investors. Gossamer Bio’s filing provides the necessary details for stakeholders to assess the financial implications of the convertible notes and warrants. The terms were finalized as of July 1, 2026.

Investor Considerations

Shareholders will evaluate the potential impact of the conversion terms on earnings per share and ownership stakes. The 7.50% coupon rate offers a yield advantage, while the conversion feature introduces equity upside. The interplay between debt and equity will be a focal point for market participants.

 

This article is for informational purposes only and does not constitute financial advice. Please consult a licensed financial adviser before making investment decisions.